Vitrakvi Interactions
There are 512 drugs known to interact with Vitrakvi (larotrectinib), along with 1 disease interaction, and 1 alcohol/food interaction. Of the total drug interactions, 67 are major, 425 are moderate, and 20 are minor.
- View all 512 medications that may interact with Vitrakvi
- View Vitrakvi alcohol/food interactions (1)
- View Vitrakvi disease interactions (1)
Most frequently checked interactions
View interaction reports for Vitrakvi (larotrectinib) and the medicines listed below.
- acetaminophen / chlorpheniramine / phenylephrine
- acetazolamide
- Actisite (tetracycline)
- Adriamycin RDF (doxorubicin)
- Advate (antihemophilic factor)
- Adzenys XR-ODT (amphetamine)
- Afinitor Disperz (everolimus)
- Alimta (pemetrexed)
- Alphanate (antihemophilic factor/von willebrand factor)
- aluminum hydroxide / magnesium hydroxide / simethicone
- amlodipine
- amlodipine / hydrochlorothiazide / olmesartan
- anastrozole
- aspirin
- atorvastatin
- Azilect (rasagiline)
- Bactrim DS (sulfamethoxazole / trimethoprim)
- Baraclude (entecavir)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- bimatoprost topical
- bisoprolol
- Botox Cosmetic (onabotulinumtoxinA)
- brimonidine ophthalmic
- budesonide
- calcitonin
- gemfibrozil
- Onpattro (patisiran)
- pyrazinamide
- Sensipar (cinacalcet)
- Xanax (alprazolam)
Vitrakvi alcohol/food interactions
There is 1 alcohol/food interaction with Vitrakvi (larotrectinib).
Vitrakvi disease interactions
There is 1 disease interaction with Vitrakvi (larotrectinib) which include:
Report options
More about Vitrakvi (larotrectinib)
- Vitrakvi consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Fam-trastuzumab deruxtecan
Trastuzumab deruxtecan (Enhertu, T-DXd) is a treatment for breast cancer, advanced stomach cancer ...
Selpercatinib
Selpercatinib systemic is used for non small cell lung cancer, solid tumors, thyroid cancer
Dabrafenib
Dabrafenib systemic is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer ...
Trametinib
Trametinib systemic is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
